바이러스 벡터 및 플라스미드 DNA 제조 시장 규모, 점유율, 동향 분석 보고서 : 벡터 유형별, 워크플로우별, 용도별, 최종 용도별, 질환별, 지역별, 부문별 예측(2026-2033년)

Viral Vectors And Plasmid DNA Manufacturing Market Summary

The global viral vector and plasmid DNA manufacturing market size was estimated at USD 6.68 billion in 2025 and is projected to reach USD 19.52 billion by 2033, growing at a CAGR of 14.5% from 2026 to 2033. One of the primary factors driving the market is the advancement in gene therapy, as the development of new gene therapies is heavily reliant on high-quality viral vectors and plasmid DNA.

Furthermore, improvements in manufacturing processes have made it possible to produce viral vectors and plasmid DNA more efficiently at larger scales, while also reducing costs and improving overall quality. The growth of the viral vectors and plasmid DNA manufacturing market has been strongly driven by rising demand for gene and cell therapies, particularly across North America and Europe. The U.S. plasmid DNA manufacturing market leads due to high clinical trial activity, strong CDMO presence, and increasing outsourcing trends within the plasmid DNA contract manufacturing market. Meanwhile, the UK viral vectors plasmid DNA manufacturing market continues to expand, supported by government-backed life sciences initiatives and advanced research infrastructure. Across regions, the broader viral vector and plasmid DNA manufacturing market and the DNA plasmid manufacturing market are benefiting from growing biotech investments, capacity expansion by manufacturers, and the need for scalable, GMP-compliant production to support research, clinical development, and commercialization.

The rapid growth of cell and gene therapies, particularly in oncology, rare diseases, and genetic disorders. Increasing numbers of clinical trials, along with rising regulatory approvals for advanced therapies such as CAR-T, AAV-based gene therapies, and mRNA platforms, have significantly boosted demand for high-quality viral vectors and plasmid DNA. As biopharmaceutical companies move programs from early research into late-stage development and commercialization, the need for scalable, GMP-compliant manufacturing capabilities has continued to expand.

In addition, sustained investments in academic research, biotechnology innovation, and personalized medicine have further supported market growth. Research institutes and emerging biotech companies increasingly rely on outsourced manufacturing partners to overcome technical complexity, high capital costs, and stringent regulatory requirements. Capacity expansions by CDMOs, advancements in vector production technologies, and growing government support for life sciences infrastructure have collectively strengthened demand for reliable and efficient viral vector and plasmid DNA manufacturing solutions worldwide.

Global Viral Vector And Plasmid DNA Manufacturing Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global viral vector and plasmid DNA manufacturing market report based on vector type, workflow, application, end-use, disease, and region.

• Vector Type Outlook (Revenue, USD Billion, 2021 - 2033)
• Adeno-associated virus (AAV)
• Lentivirus
• Adenovirus
• Retrovirus
• Plasmids
• Others
• Workflow Outlook (Revenue, USD Billion, 2021 - 2033)
• Upstream Manufacturing
  • Vector Amplification & Expansion
  • Vector Recovery/Harvesting
• Downstream Manufacturing
  • Purification
  • Fill Finish
• Application Outlook (Revenue, USD Billion, 2021 - 2033)
• Antisense & RNAi Therapy
• Gene Therapy
• Cell Therapy
• Vaccinology
• Research Applications
• End-use Outlook (Revenue, USD Billion, 2021 - 2033)
• Pharmaceutical and Biopharmaceutical Companies
• Research Institutes
• Disease Outlook (Revenue, USD Billion, 2021 - 2033)
• Cancer
• Genetic Disorders
• Infectious Diseases
• Others
• Regional Outlook (Revenue, USD Billion, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Sweden
  • Denmark
  • Norway
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East and Africa (MEA)
  • Kuwait
  • UAE
  • South Africa
  • Saudi Arabia

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Vector type
  • 1.2.2. Workflow
  • 1.2.3. Application
  • 1.2.4. End Use
  • 1.2.5. Disease
  • 1.2.6. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. List of Secondary Sources
• 1.8. List of Primary Sources
• 1.9. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Viral Vectors And Plasmid DNA Manufacturing Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Robust Pipeline for Gene Therapies and Viral Vector Vaccines
    • 3.2.1.2. Technological Advancements in Manufacturing Vectors
    • 3.2.1.3. Highly Competitive Market and Various Strategies Undertaken by Market Entities
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Regulatory, Scientific, And Ethical Challenges Associated With Gene Therapy And Viral Vectors
• 3.3. Viral Vectors And Plasmid DNA Manufacturing Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
  • 3.3.2. PESTEL Analysis

Chapter 4. Viral Vectors And Plasmid DNA Manufacturing Market: Vector Type Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Global Viral Vectors And Plasmid DNA Manufacturing Market by Vector Type Outlook
• 4.3. Adeno-associated Virus (AAV)
  • 4.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
• 4.4. Lentivirus
  • 4.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
• 4.5. Adenovirus
  • 4.5.1. Market estimates and forecasts 2021 to 2033 (USD Million)
• 4.6. Retrovirus
  • 4.6.1. Market estimates and forecasts 2021 to 2033 (USD Million)
• 4.7. Plasmids
  • 4.7.1. Market estimates and forecasts 2021 to 2033 (USD Million)
• 4.8. Others
  • 4.8.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 5. Viral Vectors And Plasmid DNA Manufacturing Market: Workflow Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Global Viral Vectors And Plasmid DNA Manufacturing Market by Workflow Outlook
• 5.3. Upstream Manufacturing
  • 5.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.3.2. Vector Amplification & Expansion
    • 5.3.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.3.3. Vector Recovery/Harvesting
    • 5.3.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
• 5.4. Downstream Manufacturing
  • 5.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.4.2. Purification
    • 5.4.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.4.3. Fill Finish diagnostic instruments
    • 5.4.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 6. Viral Vectors And Plasmid DNA Manufacturing Market: Application Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Global Viral Vectors And Plasmid DNA Manufacturing Market by Application Outlook
• 6.3. Antisense & RNAi
  • 6.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
• 6.4. Gene Therapy
  • 6.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
• 6.5. Cell Therapy
  • 6.5.1. Market estimates and forecasts 2021 to 2033 (USD Million)
• 6.6. Vaccinology
  • 6.6.1. Market estimates and forecasts 2021 to 2033 (USD Million)
• 6.7. Research Applications
  • 6.7.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 7. Viral Vectors And Plasmid DNA Manufacturing Market: End Use Estimates & Trend Analysis

• 7.1. Segment Dashboard
• 7.2. Global Viral Vectors And Plasmid DNA Manufacturing Market by End Use Outlook
• 7.3. Pharmaceutical and Biopharmaceutical Companies
  • 7.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
• 7.4. Research Institutes
  • 7.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 8. Viral Vectors And Plasmid DNA Manufacturing Market: Disease Estimates & Trend Analysis

• 8.1. Segment Dashboard
• 8.2. Global Viral Vectors And Plasmid DNA Manufacturing Market by Disease Outlook
• 8.3. Cancer
  • 8.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
• 8.4. Genetic Disorders
  • 8.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
• 8.5. Infectious Diseases
  • 8.5.1. Market estimates and forecasts 2021 to 2033 (USD Million)
• 8.6. Other
  • 8.6.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 9. Viral Vectors And Plasmid DNA Manufacturing Market: Regional Estimates & Trend Analysis

• 9.1. Regional Market Share Analysis, 2025 & 2033
• 9.2. North America
  • 9.2.1. North America market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.2.2. U.S.
    • 9.2.2.1. Key country dynamics
    • 9.2.2.2. Regulatory framework
    • 9.2.2.3. Competitive scenario
    • 9.2.2.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.2.3. Canada
    • 9.2.3.1. Key country dynamics
    • 9.2.3.2. Regulatory framework
    • 9.2.3.3. Competitive scenario
    • 9.2.3.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.2.4. Mexico
    • 9.2.4.1. Key country dynamics
    • 9.2.4.2. Regulatory framework
    • 9.2.4.3. Competitive scenario
    • 9.2.4.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
• 9.3. Europe
  • 9.3.1. Europe market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.3.2. UK
    • 9.3.2.1. Key country dynamics
    • 9.3.2.2. Regulatory framework
    • 9.3.2.3. Competitive scenario
    • 9.3.2.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.3.3. Germany
    • 9.3.3.1. Key country dynamics
    • 9.3.3.2. Regulatory framework
    • 9.3.3.3. Competitive scenario
    • 9.3.3.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.3.4. France
    • 9.3.4.1. Key country dynamics
    • 9.3.4.2. Regulatory framework
    • 9.3.4.3. Competitive scenario
    • 9.3.4.4. France market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.3.5. Italy
    • 9.3.5.1. Key country dynamics
    • 9.3.5.2. Regulatory framework
    • 9.3.5.3. Competitive scenario
    • 9.3.5.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.3.6. Spain
    • 9.3.6.1. Key country dynamics
    • 9.3.6.2. Regulatory framework
    • 9.3.6.3. Competitive scenario
    • 9.3.6.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.3.7. Norway
    • 9.3.7.1. Key country dynamics
    • 9.3.7.2. Regulatory framework
    • 9.3.7.3. Competitive scenario
    • 9.3.7.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.3.8. Sweden
    • 9.3.8.1. Key country dynamics
    • 9.3.8.2. Regulatory framework
    • 9.3.8.3. Competitive scenario
    • 9.3.8.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.3.9. Denmark
    • 9.3.9.1. Key country dynamics
    • 9.3.9.2. Regulatory framework
    • 9.3.9.3. Competitive scenario
    • 9.3.9.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
• 9.4. Asia Pacific
  • 9.4.1. Asia Pacific market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.4.2. Japan
    • 9.4.2.1. Key country dynamics
    • 9.4.2.2. Regulatory framework
    • 9.4.2.3. Competitive scenario
    • 9.4.2.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.4.3. China
    • 9.4.3.1. Key country dynamics
    • 9.4.3.2. Regulatory framework
    • 9.4.3.3. Competitive scenario
    • 9.4.3.4. China market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.4.4. India
    • 9.4.4.1. Key country dynamics
    • 9.4.4.2. Regulatory framework
    • 9.4.4.3. Competitive scenario
    • 9.4.4.4. India market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.4.5. Australia
    • 9.4.5.1. Key country dynamics
    • 9.4.5.2. Regulatory framework
    • 9.4.5.3. Competitive scenario
    • 9.4.5.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.4.6. South Korea
    • 9.4.6.1. Key country dynamics
    • 9.4.6.2. Regulatory framework
    • 9.4.6.3. Competitive scenario
    • 9.4.6.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.4.7. Thailand
    • 9.4.7.1. Key country dynamics
    • 9.4.7.2. Regulatory framework
    • 9.4.7.3. Competitive scenario
    • 9.4.7.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
• 9.5. Latin America
  • 9.5.1. Latin America market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.5.2. Brazil
    • 9.5.2.1. Key country dynamics
    • 9.5.2.2. Regulatory framework
    • 9.5.2.3. Competitive scenario
    • 9.5.2.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.5.3. Argentina
    • 9.5.3.1. Key country dynamics
    • 9.5.3.2. Regulatory framework
    • 9.5.3.3. Competitive scenario
    • 9.5.3.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
• 9.6. MEA
  • 9.6.1. MEA market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.6.2. South Africa
    • 9.6.2.1. Key country dynamics
    • 9.6.2.2. Regulatory framework
    • 9.6.2.3. Competitive scenario
    • 9.6.2.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.6.3. Saudi Arabia
    • 9.6.3.1. Key country dynamics
    • 9.6.3.2. Regulatory framework
    • 9.6.3.3. Competitive scenario
    • 9.6.3.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.6.4. UAE
    • 9.6.4.1. Key country dynamics
    • 9.6.4.2. Regulatory framework
    • 9.6.4.3. Competitive scenario
    • 9.6.4.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.6.5. Kuwait
    • 9.6.5.1. Key country dynamics
    • 9.6.5.2. Regulatory framework
    • 9.6.5.3. Competitive scenario
    • 9.6.5.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 10. Competitive Landscape

• 10.1. Company Categorization
• 10.2. Strategy Mapping
• 10.3. Company Market Position Analysis, 2025
• 10.4. Company Profiles/Listing
  • 10.4.1. Merck KGaA
    • 10.4.1.1. Company overview
    • 10.4.1.2. Financial performance
    • 10.4.1.3. Product benchmarking
    • 10.4.1.4. Strategic initiatives
  • 10.4.2. Lonza
    • 10.4.2.1. Company overview
    • 10.4.2.2. Financial performance
    • 10.4.2.3. Product benchmarking
    • 10.4.2.4. Strategic initiatives
  • 10.4.3. FUJIFILM Diosynth Biotechnologies
    • 10.4.3.1. Company overview
    • 10.4.3.2. Financial performance
    • 10.4.3.3. Product benchmarking
    • 10.4.3.4. Strategic initiatives
  • 10.4.4. Thermo Fisher Scientific
    • 10.4.4.1. Company overview
    • 10.4.4.2. Financial performance
    • 10.4.4.3. Product benchmarking
    • 10.4.4.4. Strategic initiatives
  • 10.4.5. Cobra Biologics
    • 10.4.5.1. Company overview
    • 10.4.5.2. Financial performance
    • 10.4.5.3. Product benchmarking
    • 10.4.5.4. Strategic initiatives
  • 10.4.6. Catalent Inc.
    • 10.4.6.1. Company overview
    • 10.4.6.2. Financial performance
    • 10.4.6.3. Product benchmarking
    • 10.4.6.4. Strategic initiatives
  • 10.4.7. Wuxi Biologics
    • 10.4.7.1. Company overview
    • 10.4.7.2. Financial performance
    • 10.4.7.3. Product benchmarking
    • 10.4.7.4. Strategic initiatives
  • 10.4.8. Takara Bio Inc.
    • 10.4.8.1. Company overview
    • 10.4.8.2. Financial performance
    • 10.4.8.3. Product benchmarking
    • 10.4.8.4. Strategic initiatives
  • 10.4.9. Waisman Biomanufacturing
    • 10.4.9.1. Company overview
    • 10.4.9.2. Financial performance
    • 10.4.9.3. Product benchmarking
    • 10.4.9.4. Strategic initiatives
  • 10.4.10. Genezen laboratories
    • 10.4.10.1. Company overview
    • 10.4.10.2. Financial performance
    • 10.4.10.3. Product benchmarking
    • 10.4.10.4. Strategic initiatives
  • 10.4.11. Batavia Biosciences
    • 10.4.11.1. Company overview
    • 10.4.11.2. Financial performance
    • 10.4.11.3. Product benchmarking
    • 10.4.11.4. Strategic initiatives
  • 10.4.12. Miltenyi Biotec GmbH
    • 10.4.12.1. Company overview
    • 10.4.12.2. Financial performance
    • 10.4.12.3. Product benchmarking
    • 10.4.12.4. Strategic initiatives
  • 10.4.13. SIRION Biotech GmbH
    • 10.4.13.1. Company overview
    • 10.4.13.2. Financial performance
    • 10.4.13.3. Product benchmarking
    • 10.4.13.4. Strategic initiatives
  • 10.4.14. Virovek Incorporation
    • 10.4.14.1. Company overview
    • 10.4.14.2. Financial performance
    • 10.4.14.3. Product benchmarking
    • 10.4.14.4. Strategic initiatives
  • 10.4.15. BioNTech IMFS GmbH
    • 10.4.15.1. Company overview
    • 10.4.15.2. Financial performance
    • 10.4.15.3. Product benchmarking
    • 10.4.15.4. Strategic initiatives
  • 10.4.16. Audentes Therapeutics
    • 10.4.16.1. Company overview
    • 10.4.16.2. Financial performance
    • 10.4.16.3. Product benchmarking
    • 10.4.16.4. Strategic initiatives
  • 10.4.17. BioMarin Pharmaceutical
    • 10.4.17.1. Company overview
    • 10.4.17.2. Financial performance
    • 10.4.17.3. Product benchmarking
    • 10.4.17.4. Strategic initiatives
  • 10.4.18. RegenxBio, Inc.
    • 10.4.18.1. Company overview
    • 10.4.18.2. Financial performance
    • 10.4.18.3. Product benchmarking
    • 10.4.18.4. Strategic initiatives